



John T. Curnutte, MD, PhD

Executive Vice President,
Research and Development

Portola Pharmaceuticals


Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases you can identify these statements by forward-looking words, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “potential,” “seek,” “expect,” “goal,” or the negative or plural of these words or similar expressions.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, and new risks emerge from time to time. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Please refer to our Annual Report on Form 10-K that we filed with the SEC for a description of risks and uncertainties that could impact future results.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update any forward-looking statements except as required by law.

Andexanet Alfa: Recombinant, Modified Version of Human Factor Xa Produced in CHO Cells




| Inhibitor | $K_{d,Andx}$ (nM) | $K_{i,FXa}$ (nM) | Kd/Ki |
|-------------|-------------------|------------------|-------|
| Betrixaban | 0.53 | 0.117 (reported) | 4.53 |
| Rivaroxaban | 1.53 | 0.400 (reported) | 3.83 |
| Apixaban | 0.58 | 0.100 (reported) | 5.80 |

Immediate Reversal of Anti-fXa Activity by Andexanet Alfa can be Sustained by Infusion as Long as Required

• Apixaban Phase 2


420 mg bolus + 4 mg per minute infusion over 2 hours:

- 92% reversal at 2 minutes
 - 91% reversal at 2 hours
 - Highly statistically significant
- Potential to address numerous clinical scenarios by allowing for flexible and controlled reversal
- Well tolerated; no thrombotic events, serious adverse events or antibodies to FXa or FX observed




Dose-Dependent Reversal of Anti-fXa Activity Correlates with Reduction in Plasma Free Fraction of Anti-fXa

Anti-fXa Activity




Apixaban Free Fraction




Mean ± SEM

Andexanet Alfa Mobilizes Apixaban from Extravascular Tissue Due to its Effective Binding of Apixaban




Dose-Dependent Recovery of Thrombin Generation Upon Andexanet Administration



Mean \pm SEM

Reversal of Apixaban-Induced ACT Prolongation: 420mg Bolus vs. 420mg Bolus + Infusion of Andexanet Alfa on Day 6



Andexanet Alfa: FDA/CBER Breakthrough Therapy with Potential to Reverse Factor Xa Inhibitors Without Major Side Effects

- ✓ Precise and specific MOA
- ✓ Immediate reversal: temporary or sustainable
- ✓ Demonstrated reversal of important markers: anti-FXa activity and free fraction of anticoagulant
- ✓ Phase 2 data; ongoing Phase 3 and Phase 2 studies
 - ▶ Apixaban
 - ▶ Rivaroxaban
 - ▶ Edoxaban
 - ▶ Enoxaparin
 - ▶ Betrixaban
- ✓ ▶ Safety data in over 100 healthy volunteers

